Ken Griffin Neurocrine Biosciences Inc Put Options Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
Put Options
12 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
101MCall Options Held
282KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.83 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.26 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$718 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$576 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$398 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...